Clarithromycin — an antibacterial defense proven by time

May 6, 2020

The general characteristics of a group of antibacterial drugs related to macrolides are considered. The advantages and features of clinical use of clarithromycin and its role in the treatment of pneumonia, ENT-pathology, the achievement of eradication of Helicobacter pylori infection and in pulmonary pathology (ventilator associated pneumonia, nosocomial and community-acquired pneumonia), as well as in septic conditions were determined. The feasibility of the use of form of the drug for parenteral administration in the treatment of severe respiratory tract infection was made.


  • Ministerstvo ohoroni zdorov’ya Ukrayini (2007) Nakaz MOZ Ukrayini vId 19.03.2007 (
  • Calò L., Passàli G.C, Galli J. (2011) Role of biofilms in chronic inflammatory diseases of the upper airways. Adv. Otorhinolaryngol., 72: 93–96. doi: 10.1159/000324622.
  • Chang J.Y., Shim K.-N., Tae Ch.H. et al. (2017) Triple therapy versus sequential therapy for the first-line Helicobacter pylorі eradication. BMC Gastroenterol., 17: 16.
  • Giamarellos-Bourboulis E.J., Pechère J.C., Routsi C. et al. (2008) Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis., 46(8): 1157–1164. doi: 10.1086/529439.
  • Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. (2000) Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis., 181: 176–180.
  • Heron M. (2007) Deaths: leading causes for 2004. Natl. Vital. Stat. Rep., 56(5): 1–95.
  • Malfertheiner P., Megraud F., O’Morain C.A. et al.; European Helicobacter Study Group (2012) Management of Helicobacter pylori infection — the Maastricht IV/Florence Consensus Report. Gut, 61(5): 646–664. doi: 10.1136/gutjnl-2012-302084.
  • Spyridaki A., Raftogiannis M., Antonopoulou A. et al. (2012) Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob. Agents Chemother., 56(7): 3819–3825. doi: 10.1128/AAC.05798-11.